BNP Paribas Financial Markets Has $47.87 Million Stock Position in DaVita Inc. (NYSE:DVA)

BNP Paribas Financial Markets grew its holdings in DaVita Inc. (NYSE:DVA) by 23.9% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 292,039 shares of the company’s stock after purchasing an additional 56,389 shares during the period. BNP Paribas Financial Markets owned about 0.36% of DaVita worth $47,874,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in DVA. Transcendent Capital Group LLC acquired a new stake in DaVita in the 3rd quarter valued at $25,000. Blue Trust Inc. increased its position in shares of DaVita by 58.6% in the second quarter. Blue Trust Inc. now owns 211 shares of the company’s stock valued at $29,000 after acquiring an additional 78 shares during the last quarter. Family Firm Inc. acquired a new position in DaVita during the second quarter valued at approximately $43,000. Versant Capital Management Inc grew its stake in DaVita by 90.6% in the second quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock valued at $45,000 after purchasing an additional 155 shares in the last quarter. Finally, Friedenthal Financial acquired a new position in shares of DaVita during the 2nd quarter worth approximately $48,000. Institutional investors own 90.12% of the company’s stock.

Analyst Ratings Changes

DVA has been the topic of several analyst reports. UBS Group upped their price target on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Bank of America raised their target price on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research note on Wednesday, August 7th. Truist Financial boosted their price target on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. Finally, Barclays lifted their target price on DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $161.80.

Insider Buying and Selling

In related news, CEO Javier Rodriguez sold 50,000 shares of the stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the sale, the chief executive officer now owns 837,835 shares of the company’s stock, valued at $138,284,666.75. This represents a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 2.00% of the stock is owned by insiders.

DaVita Trading Down 1.4 %

Shares of NYSE:DVA opened at $165.63 on Friday. DaVita Inc. has a 12-month low of $98.26 and a 12-month high of $169.51. The business has a 50 day moving average of $158.47 and a 200-day moving average of $148.99. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78. The stock has a market cap of $13.58 billion, a PE ratio of 17.87, a P/E/G ratio of 0.93 and a beta of 0.89.

DaVita (NYSE:DVA) last released its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.76 by ($0.17). The firm had revenue of $3.26 billion during the quarter, compared to the consensus estimate of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. The business’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter last year, the firm earned $2.85 earnings per share. As a group, equities research analysts forecast that DaVita Inc. will post 9.71 earnings per share for the current year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.